Leading the way to safer medication
 Crosscheck  Recommender

Buprenorphine

Also known as: Buprenorphine hydrochloride

Brand names: ASTEC BELBUCA BUNAVAIL (in combination) BUPENSAN BUPENSAN DUO (in combination) BUPRENEX BUPRENOCAN BUPRETEC BUTRANS BUVIDAL NORSPAN PROBUPHINE SIXMO SOVENOR SUBLOCADE SUBOXONE (in combination) SUBUTEX TEMGESIC TRANSTEC ZUBSOLV (in combination)

Therapeutic Indications

Buprenorphine is indicated for:

Severe pain

Irrespective of gender only Adults (18 years old or older)

Buprenorphine is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Percutaneous - 35-70 μικρογραμμάρια/ώρα

Opioid dependence

Irrespective of gender only Adolescents (12 years - 18 years old) Adults (18 years old or older)

Treatment of opioid dependence within a framework of medical, social and psychological treatment.

Treatment is intended for use in adults and adolescents aged 16 years or over.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 4-32 mg once daily

Treatment 2: Sublingual - 0.4-24 mg once daily

Contraindications

Active ingredient Buprenorphine is contraindicated in the following cases:

Severe hepatic impairment

No gender/age discrimination

In patients with severe hepatic impairment, the use of buprenorphine is contraindicated.

Gastrointestinal obstruction, paralytic ileus

No gender/age discrimination

Known or suspected gastrointestinal obstruction, including paralytic ileus.

Acute or severe bronchial asthma

No gender/age discrimination

Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment.

Acute alcoholism, delirium tremens

No gender/age discrimination

Hypersensitivity to buprenorphine

No gender/age discrimination

Severe respiratory insufficiency

No gender/age discrimination